Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors

TWO TOPICAL CALCINEURIN INHIBITORS FOR THE TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (VARIANT OF THE ARTICLE IN RUSSIAN)

S.L. Chen
J. Yan
F.S. Wang

January 2011

Two new topical immunomodulators, pimecrolimus cream and tacrolimus ointment for atopic dermatitis (...

The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo

오상호

June 2021

Background: Topical calcineurin inhibitors have been used to treat vitiligo, either alone or in comb...

Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants

Luger, Thomas
Boguniewicz, Mark
Carr, Warner
Cork, Michael
Deleuran, Mette
Eichenfield, Lawrence
Eigenmann, Philippe
Fölster-Holst, Regina
Gelmetti, Carlo
Gollnick, Harald
Hamelmann, Eckard
Hebert, Adelaide A
Muraro, Antonella
Oranje, Arnold P
Paller, Amy S
Paul, Carle
Puig, Luis
Ring, Johannes
Siegfried, Elaine
Spergel, Jonathan M
Stingl, Georg
Taieb, Alain
Torrelo, Antonio
Werfel, Thomas
Wahn, Ulrich

January 2015

Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during inf...

Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors

Bieber, Thomas
Cork, Michael
Ellis, Charles
Girolomoni, Giampiero
Groves, Richard
Langley, Richard
Luger, Thomas
Meurer, Michael
Murrell, Dédée
Orlow, Seth
Paller, Amy
de Prost, Yves
Puig, Lluís
Ring, Johannes
Saurat, Jean-Hilaire
Schwarz, Thomas
Shear, Neil
Stingl, Georg
Taieb, Alain
Thestrup-Pedersen, K.

January 2005

Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. ...

REVIEW ARTICLE Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice

Adelaide A. Hebert

January 2013

The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Topical ...

AReassuring Rejoinder Against Malignant Influences of Topical Calcineurin Use in Children

Jonm Hanifin Md

November 2015

The topical calcineurin inhibitors tacrolimus and pimecroli-mus are useful and effective anti-inflam...

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.

Ring, J.
Barker, J.
Behrendt, H.
Braathen, L.
Darsow, U.
Dubertret, L.
Giannetti, A.
Hawk, J.
Honigsmann, H.
Kemeny, L.
Luger, T.
Meurer, M.
Murphy, G.
Peserico, A.
Ranki, A.
Reunala, T.
Saurat, J.H.
Sterry, W.
Kerkhof, P.C.M. van de

January 2005

Topical Calcineurin Inhibitors (TCIs) used for the treatment of atopic eczema modify the immune regu...

Position statement : topical calcineurin inhibitors in atopic dermatitis

Remitz, A.
De Pita, O.
Mota, A.
Serra-Baldrich, E.
Vakirlis, E.
Kapp, A.

December 2018

Background Atopic dermatitis (AD) is a common inflammatory skin disease in both adults and children....

Lack of Association between Exposure to Topical Calcineurin Inhibitors and Skin Cancer in Adults

David J. Margolis A

September 2016

of tubes used and the potency of the agent increased. Con-clusion: This early study shows that TCI u...

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors - Position statement of the European dermatology forum

J. Ring
J. Barker
H. Behrendt
L. Braathen
U. Darsow
L. Dubertret
J. Hawk
H. Honigsmann
L. Kemeny
T. Luger
M. Meurer
G. Murphy
A. Peserico
A. Ranki
T. Reunala
J. Saurat
W. Sterry
P. van de Kerkhof
GIANNETTI, Alberto

January 2005

Topical Calcineurin Inhibitors (TCIs) used for the treatment of atopic eczema modify the immune regu...

REVIEW ARTICLE Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations

Warner W. Carr

January 2013

The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Atopic d...

Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.

Stuetz, Anton
Baumann, Karl
Grassberger, Max
Wolff, Klaus
Meingassner, Josef

January 2006

Using a newly developed model of allergic contact dermatitis in pigs, calcineurin inhibitors of the ...

Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus : Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Arana, Alejandro
Pottegård, Anton
Kuiper, Josephina G.
Booth, Helen
Reutfors, Johan
Calingaert, Brian
Lund, Lars Christian
Crellin, Elizabeth
Schmitt-Egenolf, Marcus
Kaye, James A.
Gembert, Karin
Rothman, Kenneth J.
Kieler, Helle
Dedman, Daniel
Houben, Eline
Gutiérrez, Lia
Hallas, Jesper
Perez-Gutthann, Susana

January 2021

Purpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus ...

Association BetweenMalignancy and Topical Use

Of Pimecrolimus
Denise Raimondo
Msed Warren
B. Bilker

November 2015

A topic dermatitis (AD) is a common chronic inflamma-torydermatitis of the skin. Itmost frequently o...

Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function

이승헌

January 2010

BACKGROUND: Topical calcineurin inhibitors (TCIs) such as pimecrolimus and tacrolimus have recently ...

TWO TOPICAL CALCINEURIN INHIBITORS FOR THE TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (VARIANT OF THE ARTICLE IN RUSSIAN)

S.L. Chen
J. Yan
F.S. Wang

January 2011

Two new topical immunomodulators, pimecrolimus cream and tacrolimus ointment for atopic dermatitis (...

The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo

오상호

June 2021

Background: Topical calcineurin inhibitors have been used to treat vitiligo, either alone or in comb...

Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants

Luger, Thomas
Boguniewicz, Mark
Carr, Warner
Cork, Michael
Deleuran, Mette
Eichenfield, Lawrence
Eigenmann, Philippe
Fölster-Holst, Regina
Gelmetti, Carlo
Gollnick, Harald
Hamelmann, Eckard
Hebert, Adelaide A
Muraro, Antonella
Oranje, Arnold P
Paller, Amy S
Paul, Carle
Puig, Luis
Ring, Johannes
Siegfried, Elaine
Spergel, Jonathan M
Stingl, Georg
Taieb, Alain
Torrelo, Antonio
Werfel, Thomas
Wahn, Ulrich

January 2015

Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during inf...

Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors

Bieber, Thomas
Cork, Michael
Ellis, Charles
Girolomoni, Giampiero
Groves, Richard
Langley, Richard
Luger, Thomas
Meurer, Michael
Murrell, Dédée
Orlow, Seth
Paller, Amy
de Prost, Yves
Puig, Lluís
Ring, Johannes
Saurat, Jean-Hilaire
Schwarz, Thomas
Shear, Neil
Stingl, Georg
Taieb, Alain
Thestrup-Pedersen, K.

January 2005

Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. ...

REVIEW ARTICLE Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice

Adelaide A. Hebert

January 2013

The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Topical ...

AReassuring Rejoinder Against Malignant Influences of Topical Calcineurin Use in Children

Jonm Hanifin Md

November 2015

The topical calcineurin inhibitors tacrolimus and pimecroli-mus are useful and effective anti-inflam...

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.

Ring, J.
Barker, J.
Behrendt, H.
Braathen, L.
Darsow, U.
Dubertret, L.
Giannetti, A.
Hawk, J.
Honigsmann, H.
Kemeny, L.
Luger, T.
Meurer, M.
Murphy, G.
Peserico, A.
Ranki, A.
Reunala, T.
Saurat, J.H.
Sterry, W.
Kerkhof, P.C.M. van de

January 2005

Topical Calcineurin Inhibitors (TCIs) used for the treatment of atopic eczema modify the immune regu...

Position statement : topical calcineurin inhibitors in atopic dermatitis

Remitz, A.
De Pita, O.
Mota, A.
Serra-Baldrich, E.
Vakirlis, E.
Kapp, A.

December 2018

Background Atopic dermatitis (AD) is a common inflammatory skin disease in both adults and children....

Lack of Association between Exposure to Topical Calcineurin Inhibitors and Skin Cancer in Adults

David J. Margolis A

September 2016

of tubes used and the potency of the agent increased. Con-clusion: This early study shows that TCI u...

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors - Position statement of the European dermatology forum

J. Ring
J. Barker
H. Behrendt
L. Braathen
U. Darsow
L. Dubertret
J. Hawk
H. Honigsmann
L. Kemeny
T. Luger
M. Meurer
G. Murphy
A. Peserico
A. Ranki
T. Reunala
J. Saurat
W. Sterry
P. van de Kerkhof
GIANNETTI, Alberto

January 2005

Topical Calcineurin Inhibitors (TCIs) used for the treatment of atopic eczema modify the immune regu...

REVIEW ARTICLE Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations

Warner W. Carr

January 2013

The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Atopic d...

Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.

Stuetz, Anton
Baumann, Karl
Grassberger, Max
Wolff, Klaus
Meingassner, Josef

January 2006

Using a newly developed model of allergic contact dermatitis in pigs, calcineurin inhibitors of the ...

Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus : Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Arana, Alejandro
Pottegård, Anton
Kuiper, Josephina G.
Booth, Helen
Reutfors, Johan
Calingaert, Brian
Lund, Lars Christian
Crellin, Elizabeth
Schmitt-Egenolf, Marcus
Kaye, James A.
Gembert, Karin
Rothman, Kenneth J.
Kieler, Helle
Dedman, Daniel
Houben, Eline
Gutiérrez, Lia
Hallas, Jesper
Perez-Gutthann, Susana

January 2021

Purpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus ...

Association BetweenMalignancy and Topical Use

Of Pimecrolimus
Denise Raimondo
Msed Warren
B. Bilker

November 2015

A topic dermatitis (AD) is a common chronic inflamma-torydermatitis of the skin. Itmost frequently o...

Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function

이승헌

January 2010

BACKGROUND: Topical calcineurin inhibitors (TCIs) such as pimecrolimus and tacrolimus have recently ...

TWO TOPICAL CALCINEURIN INHIBITORS FOR THE TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (VARIANT OF THE ARTICLE IN RUSSIAN)

S.L. Chen
J. Yan
F.S. Wang

January 2011

Two new topical immunomodulators, pimecrolimus cream and tacrolimus ointment for atopic dermatitis (...

The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo

오상호

June 2021

Background: Topical calcineurin inhibitors have been used to treat vitiligo, either alone or in comb...

Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants

Luger, Thomas
Boguniewicz, Mark
Carr, Warner
Cork, Michael
Deleuran, Mette
Eichenfield, Lawrence
Eigenmann, Philippe
Fölster-Holst, Regina
Gelmetti, Carlo
Gollnick, Harald
Hamelmann, Eckard
Hebert, Adelaide A
Muraro, Antonella
Oranje, Arnold P
Paller, Amy S
Paul, Carle
Puig, Luis
Ring, Johannes
Siegfried, Elaine
Spergel, Jonathan M
Stingl, Georg
Taieb, Alain
Torrelo, Antonio
Werfel, Thomas
Wahn, Ulrich

January 2015

Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during inf...

Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors

Abstract

Extracted data

Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors

Abstract

Extracted data

Related items

Related items